Clinical Trials Browser

Phase 2 × INDUSTRY × Has results × Clear all

NCT04661150 2026-04-16

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Phase 2 Active not recruiting

42 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT06502977 2026-04-15

DeLLphi-307

Phase 2 Active not recruiting

32 enrolled 9 charts

Neoplasms, Neuroendocrine Tumors

NCT02365597 2026-04-13

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 2 FDA

Urothelial Cancer

NCT02864992 2026-04-13

VISION

Phase 2 Active not recruiting

337 enrolled 13 charts 4 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03431350 2026-04-13

QUEST

Phase 2 Active not recruiting

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Phase 2 Active not recruiting

329 enrolled 23 charts

BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT04325828 2026-04-13

YATAGARASU

Phase 2 Active not recruiting

31 enrolled 15 charts

Salivary Gland Neoplasms

NCT05440786 2026-04-13

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Phase 2 Active not recruiting

46 enrolled 19 charts

Neoplasm Metastasis, Sarcoma, Ewing

NCT05663866 2026-04-13

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2 Active not recruiting

68 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06101134 2026-04-09

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Phase 2 Active not recruiting

100 enrolled 11 charts

Melanoma, Neoplasm Metastasis, Patient Preference

NCT03962543 2026-04-08

ReNeu

Phase 2 Active not recruiting

114 enrolled 25 charts 3 FDA

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT05077709 2026-04-08

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Phase 2 Completed

63 enrolled 18 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT05993299 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

7 enrolled 15 charts

Neoplasms

NCT06099782 2026-04-08

MK-3475A-F11

Phase 2 Active not recruiting

147 enrolled 14 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04619004 2026-04-07

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

277 enrolled 16 charts

Non-Small Cell Lung Cancer Metastatic

NCT02087423 2026-04-06

ATLANTIC

Phase 2 Completed

446 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04633122 2026-04-03

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Phase 2 Completed

108 enrolled 11 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Phase 2 Completed

5 enrolled 10 charts

Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

NCT04677595 2026-03-31

GeoMETry-C

Phase 2 Completed

36 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT05020015 2026-03-31

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 2 Active not recruiting

27 enrolled 23 charts

Recurrence, Lymphoma, B-Cell

NCT04785820 2026-03-27

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Phase 2 Completed

190 enrolled 40 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05152173 2026-03-27

Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis

Phase 2 Completed

176 enrolled 13 charts

Fibromatosis, Plantar

NCT05287113 2026-03-27

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Active not recruiting

176 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02360579 2026-03-25

LN-144

Phase 2 Completed

220 enrolled 16 charts 1 FDA

Melanoma

NCT02717611 2026-03-25

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Phase 2 Active not recruiting

60 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04919512 2026-03-25

SunRISe-4

Phase 2 Active not recruiting

163 enrolled 12 charts

Urinary Bladder Neoplasms

NCT05068440 2026-03-25

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Phase 2 Completed

65 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

98 enrolled 18 charts 2 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04484142 2026-03-24

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Phase 2 Completed

137 enrolled 9 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04539938 2026-03-23

HER2CLIMB-04

Phase 2 Completed

70 enrolled 23 charts

Breast Neoplasms

NCT04639219 2026-03-23

DPT01

Phase 2 Active not recruiting

102 enrolled 18 charts

Neoplasm Metastasis

NCT02180724 2026-03-20

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Phase 2 Active not recruiting

107 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT04576455 2026-03-20

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Phase 2 Active not recruiting

303 enrolled 23 charts

Breast Neoplasms

NCT04083976 2026-03-19

RAGNAR

Phase 2 Active not recruiting

316 enrolled 15 charts

Other solid neoplasm

Advanced Solid Tumor

NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Phase 2 Completed

36 enrolled 19 charts

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT02601313 2026-03-18

ZUMA-2

Phase 2 Completed

105 enrolled 33 charts 3 FDA

Lymphoma, Mantle-Cell

NCT02467270 2026-03-17

OPTIC

Phase 2 Completed

283 enrolled 31 charts

MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 2 FDA

Uveal Melanoma, Melanoma

NCT04710576 2026-03-16

AGAVE-201

Phase 2 Active not recruiting

241 enrolled 11 charts 3 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT03945773 2026-03-13

CaboPoint

Phase 2 Completed

127 enrolled 17 charts

Carcinoma, Renal Cell

NCT04300647 2026-03-12

SKYSCRAPER-04

Phase 2 Completed

172 enrolled 27 charts

Uterine Cervical Neoplasms

NCT04796324 2026-03-12

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Phase 2 Terminated

13 enrolled 8 charts

Breast Neoplasms

NCT04832854 2026-03-11

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Phase 2 Terminated

50 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT05526248 2026-03-11

ARAMON

Phase 2 Completed

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2 Active not recruiting

273 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT05537766 2026-03-10

ZUMA-25

Phase 2 Terminated

19 enrolled 28 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

NCT01843374 2026-03-05

Tremelimumab

Phase 2 Active not recruiting

571 enrolled 19 charts

Other solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT04703322 2026-03-04

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Phase 2 Active not recruiting

9 enrolled 10 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Phase 2 Completed

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT04191135 2026-03-03

KEYLYNK-009

Phase 2 Completed

462 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms